Matthew W. Nelson

Risperidone, Quetiapine, and Fluphenazine in the Treatment of Patients With Therapy-Refractory Schizophrenia

Robert R. Conley, Deanna L. Kelly, Matthew W. Nelson et al. · Clinical Neuropharmacology · 2005 · 64 citations

Pharmacy, Pharmacotherapy, Psychiatry +16

A Randomized Double-Blind Trial of Atomoxetine for Cognitive Impairments in 32 People With Schizophrenia

Deanna L. Kelly, Robert W. Buchanan, Douglas L. Boggs et al. · The Journal of Clinical Psychiatry · 2009 · 46 citations

Medicine, Pharmacology, Psychiatry +17

A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm

John L. Jefferies, Alison K. Spencer, Heather Lau et al. · Orphanet Journal of Rare Diseases · 2021 · 46 citations · Full text

Computing, Biomedical Informatics, Health Informatics +17

Adjunctive Quetiapine Decreases Symptoms of Tardive Dyskinesia in a Patient Taking Risperidone

Matthew W. Nelson, Rhonda R. Reynolds, Deanna L. Kelly et al. · Clinical Neuropharmacology · 2003 · 24 citations

Medicine, Pharmacology, Pharmacotherapy +16

Comparison of Discharge Rates and Drug Costs for Patients With Schizophrenia Treated With Risperidone or Olanzapine

Deanna L. Kelly, Matthew W. Nelson, Raymond C. Love et al. · Psychiatric Services · 2001 · 18 citations

Pharmacy, Pharmacotherapy, Psychiatry +17